Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer.

The announcement follows a 200% gain for Adaptimmune Therapeutics plc (NASDAQ:ADAP) Monday after the company reported updated data showing initial

Read the full 458 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers